CoChat

Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use

Hailozian, Christian, Luftig, Joshua, Liang, Amy, Outhay, Melena, Ullal, Monish, Anderson, Erik S., Kalmin, Mariah, Shoptaw, Steve, Greenwald, Mark K., Herring, Andrew A. · 2022 · Journal of Addiction Medicine

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Background: Optimal treatment of buprenorphine precipitated opioid withdrawal (BPOW) is unclear. Full agonist treatment of BPOW is limited by buprenorphine’s high-affinity blockade at mu-opioid receptors (μORs). Buprenorphine’s partial agonism (low intrinsic efficacy) at μORs can limit the effectiveness of even massive doses once BPOW has begun. Adjunct medications, such as clonidine, are rarely effective in severe BPOW. Ketamine is an N-methyl-D-aspartate receptor antagonist with a potentially ideal pharmacologic profile for treatment of BPOW. Ketamine reduces opioid withdrawal symptoms independently of direct μOR binding, synergistically potentiates the effectiveness of buprenorphine μOR signaling, reverses (resensitizes) fentanyl induced μOR receptor desensitization, and inhibits descending pathways of hyperalgesia and central sensitization. Ketamine’s rapid antidepressant effects potentially address depressive symptoms and subjective distress that often accompanies BPOW. Ketamine is inexpensive, safe, and available in emergency departments. To date, neither ketamine as treatment for BPOW nor to support uncomplicated buprenorphine induction has been described. Case Description: We report a case of an illicit fentanyl-using OUD patient who experienced severe BPOW during an outpatient low-dose cross taper buprenorphine induction (ie, “microdose”). The BPOW was successfully treated in the emergency department with a combination of ketamine (0.6 mg/kg intravenous over 1 hour) combined with high-dose buprenorphine (16 mg sublingual single dose); 3 days later he was administered a month-long dose of extended-release subcutaneous buprenorphine which was repeated monthly (300 mg). At 90 days the patient remained in treatment and reported continuous abstinence from fentanyl use. Conclusions: This single case observation raises important questions about the potential therapeutic role of ketamine as a treatment for BPOW. BPOW is an important clinical problem for which there is currently only limited guidance and no universally accepted approach. Prospective study comparing the effectiveness of differing pharmacologic approaches to treat BPOW is urgently needed.

Overview

Integrity signals

Registry

Crossref · 10.1097/adm.0000000000000929

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Cited by

See all 39

Metadata

Authors
Hailozian, C., Luftig, J., Liang, A., Outhay, M., Ullal, M., Anderson, E. S., Kalmin, M., Shoptaw, S., Greenwald, M. K., & Herring, A. A.
Affiliations
Eugene Applebaum College of Pharmacy and Health Sciences (US)
Corresponding author
Herring, Andrew A.
Venue
Journal of Addiction Medicine
Published
2021-11-16
Volume
16
Issue
4
Pages
483-487
ISSN
1932-0620 (ISSN-L)
OpenAlex
W3213991078
Cited by
38
References
20
Citations by year
2026: 2 · 2025: 9 · 2024: 8 · 2023: 13 · 2022: 6
FWCI
5.87
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Addiction Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
Keywords
ketamine, buprenorphine, NMDA receptor antagonists, opioid withdrawal treatment, opioid use disorder, emergency department care
MeSH terms
Analgesics, Opioid, Buprenorphine, Fentanyl, Humans, Ketamine, Male, Opioid-Related Disorders, Narcotics, Prospective Studies, Substance Withdrawal Syndrome, Receptors, Opioid, mu

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use. https://app.cochat.ai/papers/10.1097/adm.0000000000000929
The paper
Hailozian, C., Luftig, J., Liang, A., Outhay, M., Ullal, M., Anderson, E. S., Kalmin, M., Shoptaw, S., Greenwald, M. K., & Herring, A. A. (2022). Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000929

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.